National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)
Patient VersionHealth Professional VersionEn españolLast Modified: 09/09/2008



Purpose of This PDQ Summary






General Information






Cellular Classification






Stage Information






Treatment Option Overview






Localized Non-Hodgkin Lymphoma in Children and Adolescents






Disseminated Childhood B-cell Non-Hodgkin Lymphoma






Disseminated Childhood Lymphoblastic Lymphoma






Disseminated Childhood Anaplastic Large Cell Lymphoma






Recurrent Childhood Non-Hodgkin Lymphoma






Lymphoproliferative Disease Associated With Immunodeficiency in Children






Get More Information From NCI







Changes to This Summary (09/09/2008)






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Changes to This Summary (09/09/2008)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Purpose of This PDQ Summary

Added text to state that some reference citations in the summary are accompanied by a level-of-evidence designation that is intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches.

Cellular Classification

Added Sevilla et al. as reference 8.

Disseminated Childhood B-cell Non-Hodgkin Lymphoma

Added text to state that results from the pediatric international FAB/LMB study and BFM groups demonstrate that CNS disease at diagnosis is the strongest predictor of relapse for pediatric NHL, with the exception being lymphoblastic lymphoma (cited Salzburg et al. as reference 9).

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov